# Drug Discovery Platforms

Source: https://onco.cc/fronts/drug-discovery/  
OnCo record `drug-discovery` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Drug discovery platforms are the tools used to find the next drug: gene screens, organoids, models in mice, and AI.

## Summary

Drug discovery platforms are the tools used to find the next drug: gene screens, organoids, models in mice and AI. The section spans CRISPR functional genomics including DepMap, patient-derived organoids and xenografts, ex vivo drug sensitivity testing, structure-based and AI-driven design, degrader platforms and conjugation chemistry. Its own technology list holds Chai-1 and Chai-2, RFdiffusion and ProteinMPNN from the Baker Lab, BioEmu, Phenom-2 and Recursion OS, and Chemistry42 from Insilico. Technologies that link back include CRISPR screens, patient-derived organoids and xenografts, functional drug testing, PDAC organoid pharmacotyping, BH3 profiling, whole-genome sequencing, single-cell and spatial profiling, proteomics, synthetic lethality approaches and site-specific conjugation.

## Fields

- Kind: Front
- Last checked: 2026-09-04

## Sources

- NCI: Cancer treatment research: https://www.cancer.gov/research/areas/treatment
- NCI Developmental Therapeutics Program: https://dtp.cancer.gov/

## Connected records

- technologies: [Adaptive therapy (evolution-based dosing)](https://onco.cc/technologies/adaptive-therapy-dynamics/), [Agent-based and multicellular simulations](https://onco.cc/technologies/agent-based-tumour-models/), [AI compute and model platforms for oncology](https://onco.cc/technologies/ai-compute-platforms/), [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [AlphaFold 3](https://onco.cc/technologies/alphafold3/), [Angiogenesis and vascular normalisation models](https://onco.cc/technologies/angiogenesis-models/), [Bacteriophage-based tumour delivery](https://onco.cc/technologies/phage-delivery/), [BH3 profiling (functional apoptosis testing)](https://onco.cc/technologies/bh3-profiling/), [Biobanking and tissue procurement](https://onco.cc/technologies/biobanking/), [BioEmu (Microsoft)](https://onco.cc/technologies/bioemu/), [Body-surface-area dosing](https://onco.cc/technologies/body-surface-area-dosing/), [Boltz-1 / Boltz-2 (MIT, open)](https://onco.cc/technologies/boltz/), [Cancer cell line encyclopedias and dependency maps](https://onco.cc/technologies/cancer-cell-line-encyclopedias/), [Chai-1 / Chai-2](https://onco.cc/technologies/chai-1/), [Chemistry42 and Pharma.AI (Insilico)](https://onco.cc/technologies/chemistry42/), [Clonal evolution and branching models](https://onco.cc/technologies/clonal-evolution-models/), [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/), [De novo designed protein binders](https://onco.cc/technologies/de-novo-protein-design/), [Digital twins and virtual control arms](https://onco.cc/technologies/digital-twins-trials/), [DNA origami nanorobots](https://onco.cc/technologies/dna-origami-nanorobots/), [Engineered bacteria as living cancer drugs](https://onco.cc/technologies/engineered-bacteria-therapy/), [Engineered exosomes as drug carriers](https://onco.cc/technologies/exosome-therapeutics/), [ESM3 (EvolutionaryScale)](https://onco.cc/technologies/esm3/), [Evolutionary dynamics of drug resistance](https://onco.cc/technologies/drug-resistance-dynamics/), [Evolutionary game theory in cancer](https://onco.cc/technologies/evolutionary-game-theory-cancer/), [Ex vivo drug sensitivity screening in blood cancers (EXALT)](https://onco.cc/technologies/functional-precision-medicine-haematology/), [Fenbendazole, ivermectin and other internet 'repurposed cures'](https://onco.cc/technologies/fenbendazole-ivermectin-repurposing-claims/), [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Geneformer](https://onco.cc/technologies/geneformer/), [Genetically engineered mouse models](https://onco.cc/technologies/genetically-engineered-mouse-models/), [Genomics cloud and secure research environments](https://onco.cc/technologies/genomics-cloud-platforms/), [GMP, inspections, Form 483s and warning letters](https://onco.cc/technologies/pharmaceutical-gmp-inspections/), [Goldie-Coldman model of resistance](https://onco.cc/technologies/goldie-coldman-model/), [Gompertzian tumour growth](https://onco.cc/technologies/gompertzian-growth-model/), [High-throughput screening and DNA-encoded libraries](https://onco.cc/technologies/high-throughput-screening-libraries/), [Humanised mouse models](https://onco.cc/technologies/humanised-mouse-models/), [In vivo base and prime editing for cancer](https://onco.cc/technologies/in-vivo-gene-editing-cancer/), [Log-kill hypothesis (Skipper)](https://onco.cc/technologies/log-kill-hypothesis/), [Long-read sequencing (PacBio, Oxford Nanopore)](https://onco.cc/technologies/long-read-sequencing/), [Mathematical models of cancer (mathematical oncology)](https://onco.cc/technologies/mathematical-oncology/), [Metastatic seeding and dormancy models](https://onco.cc/technologies/metastasis-seeding-models/), [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [N-of-1 and rapid platform trials](https://onco.cc/technologies/n-of-1-platforms/), [Norton-Simon hypothesis and dose-dense chemotherapy](https://onco.cc/technologies/norton-simon-hypothesis/), [NVIDIA BioNeMo](https://onco.cc/technologies/bionemo/), [Organoid-guided therapy at scale](https://onco.cc/technologies/organoid-guided-therapy-scale/), [Patient digital twins](https://onco.cc/technologies/digital-twin-patient-models/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Patient-derived xenografts](https://onco.cc/technologies/pdx-models/), [Payload-linker synthesis (high-potency API)](https://onco.cc/technologies/high-potency-payload-synthesis/), [PDAC organoid pharmacotyping](https://onco.cc/technologies/pdac-organoid-pharmacotyping/), [Pharmacokinetic and pharmacodynamic modelling](https://onco.cc/technologies/pkpd-modelling/), [Phenom-2 and Recursion OS](https://onco.cc/technologies/phenom-2/), [Programmable DNA-targeting therapeutics](https://onco.cc/technologies/programmable-dna-targeting-therapeutics/), [Proliferation-invasion (reaction-diffusion) models of glioma](https://onco.cc/technologies/reaction-diffusion-glioma-model/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/), [Proteomics instruments and affinity platforms](https://onco.cc/technologies/proteomics-platforms/), [Quantitative systems pharmacology (QSP)](https://onco.cc/technologies/quantitative-systems-pharmacology/), [Residual disease kinetics (BCR-ABL halving and ctDNA slopes)](https://onco.cc/technologies/mrd-kinetics-models/), [RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)](https://onco.cc/technologies/rfdiffusion/), [scGPT](https://onco.cc/technologies/scgpt/), [Self-amplifying and circular RNA therapeutics](https://onco.cc/technologies/self-amplifying-rna/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/), [Solid stress and tumour mechanobiology models](https://onco.cc/technologies/tumour-mechanics-models/), [Spatial biology instruments](https://onco.cc/technologies/spatial-biology-instruments/), [Spatial transcriptomics](https://onco.cc/technologies/spatial-transcriptomics/), [State (Arc Institute perturbation model)](https://onco.cc/technologies/state-arc/), [STRIDE DNA break detection (intoDNA)](https://onco.cc/technologies/stride-dna-break-detection/), [Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)](https://onco.cc/technologies/structural-biology-infrastructure/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/), [Systematic drug repurposing](https://onco.cc/technologies/drug-repurposing/), [Targeting the tumour's own microbes](https://onco.cc/technologies/tumour-microbiome-targeting/), [Targeting tumour mechanics and pressure](https://onco.cc/technologies/mechanobiology-therapy/), [The four Rs and accelerated repopulation](https://onco.cc/technologies/fractionation-repopulation-models/), [Tumour clonal evolution tracking](https://onco.cc/technologies/clonal-evolution-tracking/), [Tumour control and normal tissue complication probability (TCP and NTCP)](https://onco.cc/technologies/tumour-control-probability-models/), [Tumour volume doubling time](https://onco.cc/technologies/tumour-doubling-time/), [Tumour-immune dynamics models](https://onco.cc/technologies/immune-tumour-dynamics-models/), [Tumour-on-a-chip](https://onco.cc/technologies/tumour-on-chip/), [Viral vector manufacturing (lentiviral, retroviral, AAV)](https://onco.cc/technologies/viral-vector-manufacturing/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- journals: [Cancer biology & therapy](https://onco.cc/journals/cancer-biology-and-therapy/), [Current cancer drug targets](https://onco.cc/journals/current-cancer-drug-targets/), [Oncology research](https://onco.cc/journals/oncology-research/), [Recent patents on anti-cancer drug discovery](https://onco.cc/journals/recent-patents-on-anti-cancer-drug-discovery/), [Technology in cancer research & treatment](https://onco.cc/journals/technology-in-cancer-research-and-treatment/)
- key papers: [AlphaFold 2: predicting protein structures to near-experimental accuracy](https://onco.cc/key-papers/paper-alphafold2-jumper-nature-2021/), [Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful](https://onco.cc/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/), [Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials](https://onco.cc/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/), [CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug](https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/), [Comprehensive genomic profiles of small cell lung cancer](https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/), [Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without](https://onco.cc/key-papers/paper-depmap-tsherniak-cell-2017/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [Genetics and pathogenesis of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/), [Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells](https://onco.cc/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/), [Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer](https://onco.cc/key-papers/paper-soda-eml4-alk-fusion-nature-2007/), [Molecular determinants of resistance to antiandrogen therapy](https://onco.cc/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/), [Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes](https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/), [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/), [Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable](https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/), [Prasad: most surrogate endpoints in cancer trials correlate poorly with survival](https://onco.cc/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/), [Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication](https://onco.cc/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/), [TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features](https://onco.cc/key-papers/paper-tcga-pancancer-atlas-cell-2018/), [The first PROTAC: a chimeric molecule that tags a protein for destruction](https://onco.cc/key-papers/paper-protac-concept-sakamoto-pnas-2001/), [The Hallmarks of Cancer: six capabilities every tumour must acquire](https://onco.cc/key-papers/paper-hallmarks-of-cancer-cell-2000/), [Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes](https://onco.cc/key-papers/paper-unger-trial-participation-barriers-jnci-2019/), [Veber 2002: molecular properties that influence the oral bioavailability of drug candidates](https://onco.cc/key-papers/paper-veber-oral-bioavailability-jmedchem-2002/)
- ideas: [An open foundation model of the cancer cell trained on perturbation data](https://onco.cc/ideas/idea-data-open-cell-foundation-model/), [Run small-cell lung cancer as one platform with shared controls and subtype stratification](https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/)
- terms: [Absolute versus relative benefit (number needed to treat)](https://onco.cc/terms/absolute-benefit/), [Accrual and enrolment](https://onco.cc/terms/accrual/), [Basket trial](https://onco.cc/terms/basket-trial/), [Bayesian trial design](https://onco.cc/terms/bayesian-trial-design/), [BLA / NDA / MAA (marketing applications) and PDUFA dates](https://onco.cc/terms/bla-nda/), [Blinding (double-blind, open-label, placebo-controlled)](https://onco.cc/terms/double-blind/), [Chromoplexy](https://onco.cc/terms/chromoplexy/), [Clinical equipoise](https://onco.cc/terms/clinical-equipoise/), [Cluster-randomised trial](https://onco.cc/terms/cluster-randomised-trial/), [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [Complete response letter (CRL)](https://onco.cc/terms/complete-response-letter/), [Conditional marketing authorisation (EU)](https://onco.cc/terms/conditional-approval/), [Confirmatory trial](https://onco.cc/terms/confirmatory-trial/), [Control arm and comparator (investigator's choice)](https://onco.cc/terms/control-arm/), [Crossover in trials](https://onco.cc/terms/crossover/), [Data maturity (immature vs mature survival data)](https://onco.cc/terms/data-maturity/), [Data monitoring committee (DSMB, IDMC)](https://onco.cc/terms/data-monitoring-committee/), [Decentralised trial](https://onco.cc/terms/decentralised-trial/), [Dose-escalation designs (3+3, BOIN, dose-expansion)](https://onco.cc/terms/dose-escalation-design/), [Dose-limiting toxicity (DLT)](https://onco.cc/terms/dose-limiting-toxicity/), [Duration of response (DoR) and disease control rate (DCR)](https://onco.cc/terms/duration-of-response-term/), [Enrichment and biomarker-stratified designs](https://onco.cc/terms/biomarker-stratified-design/), [Estimands and intercurrent events (ICH E9(R1))](https://onco.cc/terms/estimand/), [Ethics review (IRB, research ethics committee)](https://onco.cc/terms/ethics-review/), [External and synthetic control arms](https://onco.cc/terms/external-control-arm/), [Fast Track and RMAT designations](https://onco.cc/terms/fast-track-rmat/), [First-in-human (FIH) trial](https://onco.cc/terms/first-in-human/), [Full (traditional, regular) approval](https://onco.cc/terms/full-approval/), [Futility analysis (stopped for futility)](https://onco.cc/terms/futility/), [Group sequential design, stopping rules and alpha spending](https://onco.cc/terms/group-sequential-design/), [Health technology assessment (HTA), reimbursement and QALYs](https://onco.cc/terms/hta/), [Indication withdrawal](https://onco.cc/terms/approval-withdrawal/), [Informed consent](https://onco.cc/terms/informed-consent/), [Intention-to-treat (ITT) and per-protocol analysis](https://onco.cc/terms/intention-to-treat/), [Interim analysis, readout and data cut-off](https://onco.cc/terms/interim-analysis/), [Kaplan-Meier curve, censoring and proportional hazards](https://onco.cc/terms/kaplan-meier-curve/), [Label, indication and label expansion](https://onco.cc/terms/label-indication/), [Landmark and milestone survival (5-year survival, median follow-up)](https://onco.cc/terms/landmark-survival/), [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/), [Maximum tolerated dose (MTD)](https://onco.cc/terms/mtd/), [N-of-1 trial](https://onco.cc/terms/n-of-1-trial/), [Non-inferiority margin and equivalence trials](https://onco.cc/terms/non-inferiority-margin/), [Non-inferiority trial](https://onco.cc/terms/non-inferiority/), [ODAC (Oncologic Drugs Advisory Committee)](https://onco.cc/terms/odac/), [Orphan drug designation](https://onco.cc/terms/orphan-designation/), [Pharmacokinetics (PK), half-life and exposure](https://onco.cc/terms/pharmacokinetics/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/), [Pragmatic trial](https://onco.cc/terms/pragmatic-trial/), [Pre-specified vs post-hoc analysis](https://onco.cc/terms/prespecified-vs-post-hoc/), [Primary, secondary and co-primary endpoints](https://onco.cc/terms/primary-endpoint/), [Progressive disease and radiographic progression](https://onco.cc/terms/progressive-disease/), [Quality of life and patient-reported outcomes (QoL, PRO)](https://onco.cc/terms/qol-pro/), [Quality-adjusted survival (QALYs and Q-TWiST)](https://onco.cc/terms/quality-adjusted-survival/), [Recommended phase 2 dose (RP2D)](https://onco.cc/terms/rp2d/), [Registry-based randomised trial](https://onco.cc/terms/registry-based-trial/), [Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)](https://onco.cc/terms/regulatory-agencies/), [Response-adaptive randomisation](https://onco.cc/terms/response-adaptive-randomisation/), [Seamless, adaptive and Bayesian trial designs](https://onco.cc/terms/seamless-adaptive/), [Single-arm trial](https://onco.cc/terms/single-arm/), [SMART design (sequential multiple assignment randomised trial)](https://onco.cc/terms/smart-design/), [Statistical power, sample size and re-estimation](https://onco.cc/terms/sample-size-re-estimation/), [Statistical significance (P values, alpha, multiplicity)](https://onco.cc/terms/statistical-significance/), [Stepped-wedge design](https://onco.cc/terms/stepped-wedge-design/), [Stratified randomisation, allocation concealment and minimisation](https://onco.cc/terms/stratified-randomisation/), [Subgroup analysis (forest plots)](https://onco.cc/terms/subgroup-analysis/), [Surrogate endpoint](https://onco.cc/terms/surrogate-endpoint/), [Surrogate endpoint validation: which stand-ins have earned trust](https://onco.cc/terms/surrogate-validation/), [Therapeutic index (therapeutic window)](https://onco.cc/terms/therapeutic-index/), [Time to progression (TTP) and time to next treatment (TTNT)](https://onco.cc/terms/ttp/), [Trial lifecycle: from protocol to label](https://onco.cc/terms/trial-lifecycle/), [Trial protocol and statistical analysis plan](https://onco.cc/terms/trial-protocol/), [Trial registration and results reporting (ClinicalTrials.gov, EU CTR)](https://onco.cc/terms/trial-registration/), [Umbrella trial](https://onco.cc/terms/umbrella-trial/), [Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover](https://onco.cc/terms/trial-failure-modes/), [Window-of-opportunity trial](https://onco.cc/terms/window-of-opportunity-trial/)
- companies: [10x Genomics](https://onco.cc/companies/10x-genomics/), [Algen Biotechnologies](https://onco.cc/companies/algen-biotechnologies/), [Ambagon Therapeutics](https://onco.cc/companies/ambagon-therapeutics/), [Aqemia](https://onco.cc/companies/aqemia/), [Arpeggio Bio](https://onco.cc/companies/arpeggio-bio/), [Aurigene Oncology](https://onco.cc/companies/aurigene/), [BigHat Biosciences](https://onco.cc/companies/bighat-biosciences/), [Biocon](https://onco.cc/companies/biocon/), [Blank Bio](https://onco.cc/companies/blank-bio/), [Bruker (Bruker Spatial Biology)](https://onco.cc/companies/bruker/), [Certis Oncology Solutions](https://onco.cc/companies/certis-oncology-solutions/), [Chai Discovery](https://onco.cc/companies/chai-discovery/), [Champions Oncology](https://onco.cc/companies/champions-oncology/), [Charles River Laboratories](https://onco.cc/companies/charles-river/), [Compugen](https://onco.cc/companies/compugen/), [Cradle](https://onco.cc/companies/cradle-bio/), [CytoReason](https://onco.cc/companies/cytoreason/), [Discovery Life Sciences](https://onco.cc/companies/discovery-life-sciences/), [Elucidate Bio](https://onco.cc/companies/elucidate-bio/), [Enlaza Therapeutics](https://onco.cc/companies/enlaza-therapeutics/), [Even One Ventures](https://onco.cc/companies/evenone-ventures/), [EvolutionaryScale](https://onco.cc/companies/evolutionaryscale/), [Exscientia](https://onco.cc/companies/exscientia/), [FinalDose](https://onco.cc/companies/finaldose/), [Genesis Molecular AI (formerly Genesis Therapeutics)](https://onco.cc/companies/genesis-molecular-ai/), [Google (Health, DeepMind, Verily)](https://onco.cc/companies/google-health/), [Google DeepMind (and Google Research)](https://onco.cc/companies/google-deepmind/), [Harmonic Discovery](https://onco.cc/companies/harmonic-discovery/), [HistoWiz](https://onco.cc/companies/histowiz/), [HUB Organoids](https://onco.cc/companies/hub-organoids/), [Iambic Therapeutics](https://onco.cc/companies/iambic-therapeutics/), [Iktos](https://onco.cc/companies/iktos/), [Illumina](https://onco.cc/companies/illumina/), [Immunai](https://onco.cc/companies/immunai/), [Indivumed](https://onco.cc/companies/indivumed/), [Insilico Medicine](https://onco.cc/companies/insilico-medicine/), [Isomorphic Labs](https://onco.cc/companies/isomorphic-labs/), [Known Medicine](https://onco.cc/companies/known-medicine/), [Latent Labs](https://onco.cc/companies/latent-labs/), [Lila Sciences](https://onco.cc/companies/lila-sciences/), [Nested Therapeutics](https://onco.cc/companies/nested-therapeutics/), [Nimbus Therapeutics](https://onco.cc/companies/nimbus-therapeutics/), [Noetik](https://onco.cc/companies/noetik/), [Notable Labs](https://onco.cc/companies/notable-labs/), [Nucleai](https://onco.cc/companies/nucleai/), [Origin Bio](https://onco.cc/companies/origin-bio/), [Pathos AI](https://onco.cc/companies/pathos-ai/), [Photys Therapeutics](https://onco.cc/companies/photys-therapeutics/), [Profluent](https://onco.cc/companies/profluent-bio/), [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/), [ResistanceBio (Viosera Therapeutics)](https://onco.cc/companies/resistancebio/), [Reverie Labs](https://onco.cc/companies/reverie-labs/), [SEngine Precision Medicine](https://onco.cc/companies/sengine/), [Serinus Biosciences](https://onco.cc/companies/serinus-biosciences/), [Stablix](https://onco.cc/companies/stablix/), [Standard BioTools (SomaLogic)](https://onco.cc/companies/standard-biotools/), [Strand AI](https://onco.cc/companies/strand-ai/), [Synaffix (Lonza)](https://onco.cc/companies/synaffix/), [Syngene International](https://onco.cc/companies/syngene/), [Thermo Fisher Scientific](https://onco.cc/companies/thermo-fisher/), [Turbine](https://onco.cc/companies/turbine/), [Valo Health](https://onco.cc/companies/valo-health/), [Velorum Therapeutics](https://onco.cc/companies/velorum-therapeutics/), [Vevo Therapeutics](https://onco.cc/companies/vevo-therapeutics/), [Vizgen](https://onco.cc/companies/vizgen/), [WuXi AppTec](https://onco.cc/companies/wuxi-apptec/), [Xaira Therapeutics](https://onco.cc/companies/xaira-therapeutics/), [Xilis](https://onco.cc/companies/xilis/), [Y Combinator](https://onco.cc/companies/y-combinator/), [Yemaachi Biotech](https://onco.cc/companies/yemaachi-biotech/), [zPREDICTA](https://onco.cc/companies/zpredicta/)
- people: [Aaron Ciechanover](https://onco.cc/people/aaron-ciechanover/), [Alberto Gabizon](https://onco.cc/people/alberto-gabizon/), [Avram Hershko](https://onco.cc/people/avram-hershko/), [Gertrude Elion](https://onco.cc/people/gertrude-elion/), [Moshe Oren](https://onco.cc/people/moshe-oren/), [Yardena Samuels](https://onco.cc/people/yardena-samuels/), [Yechezkel Barenholz](https://onco.cc/people/yechezkel-barenholz/), [Yosef Yarden](https://onco.cc/people/yosef-yarden/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Preclinical results do not reproduce](https://onco.cc/bottlenecks/b-reproducibility/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/), [Radical oncology: what could change the war by 2035](https://onco.cc/roadmaps/frontier-2035/), [Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell](https://onco.cc/roadmaps/virtual-cell/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [Arc Institute](https://onco.cc/institutions/arc-institute/), [Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service](https://onco.cc/institutions/auckland-city-hospital/), [Beatson West of Scotland Cancer Centre / CRUK Scotland Institute](https://onco.cc/institutions/beatson-glasgow/), [Cancer Center at Illinois](https://onco.cc/institutions/cancer-center-at-illinois/), [Cancer Prevention and Research Institute of Texas](https://onco.cc/institutions/cprit/), [Cancer Research UK Manchester Institute](https://onco.cc/institutions/cruk-manchester-institute/), [Centro Nacional de Investigaciones Oncológicas (CNIO)](https://onco.cc/institutions/cnio/), [Damon Runyon Cancer Research Foundation](https://onco.cc/institutions/damon-runyon/), [David H. Koch Institute for Integrative Cancer Research at MIT](https://onco.cc/institutions/mit-koch/), [Department of Biotechnology, Government of India](https://onco.cc/institutions/dbt-india/), [EMBL's European Bioinformatics Institute](https://onco.cc/institutions/embl-ebi/), [European Association for Cancer Research](https://onco.cc/institutions/eacr/), [Fondation ARC pour la recherche sur le cancer](https://onco.cc/institutions/fondation-arc/), [Fondazione AIRC per la ricerca sul cancro](https://onco.cc/institutions/airc/), [Frederick National Laboratory for Cancer Research](https://onco.cc/institutions/frederick-national-lab/), [Garvan Institute of Medical Research / Kinghorn Cancer Centre](https://onco.cc/institutions/garvan-institute/), [Hebrew University of Jerusalem](https://onco.cc/institutions/hebrew-university-of-jerusalem/), [Howard Hughes Medical Institute](https://onco.cc/institutions/hhmi/), [Indian Institute of Science](https://onco.cc/institutions/iisc/), [Indian Institute of Technology Bombay](https://onco.cc/institutions/iit-bombay/), [Institute for Protein Design (University of Washington)](https://onco.cc/institutions/institute-for-protein-design/), [Institute for Stem Cell Science and Regenerative Medicine](https://onco.cc/institutions/instem/), [KWF Dutch Cancer Society](https://onco.cc/institutions/kwf/), [Max Delbrück Center for Molecular Medicine](https://onco.cc/institutions/mdc-berlin/), [National Centre for Biological Sciences](https://onco.cc/institutions/ncbs/), [National University Hospital / National University Cancer Institute, Singapore](https://onco.cc/institutions/nuh-ncis/), [Newcastle Cancer Centre / Northern Centre for Cancer Care](https://onco.cc/institutions/newcastle-cancer-centre/), [Ontario Institute for Cancer Research](https://onco.cc/institutions/oicr/), [Purdue Institute for Cancer Research](https://onco.cc/institutions/purdue-cancer-research/), [Rambam Health Care Campus](https://onco.cc/institutions/rambam/), [Rosalind and Morris Goodman Cancer Institute, McGill University](https://onco.cc/institutions/mcgill-goodman/), [Salk Institute Cancer Center](https://onco.cc/institutions/salk-institute/), [Sanford Burnham Prebys Medical Discovery Institute](https://onco.cc/institutions/sanford-burnham-prebys/), [Technion, Israel Institute of Technology](https://onco.cc/institutions/technion/), [The Jackson Laboratory Cancer Center](https://onco.cc/institutions/jackson-laboratory/), [The Mark Foundation for Cancer Research](https://onco.cc/institutions/mark-foundation/), [The V Foundation for Cancer Research](https://onco.cc/institutions/v-foundation/), [Walter and Eliza Hall Institute of Medical Research](https://onco.cc/institutions/wehi/), [Weizmann Institute of Science](https://onco.cc/institutions/weizmann/), [Wellcome](https://onco.cc/institutions/wellcome/), [Wellcome Sanger Institute](https://onco.cc/institutions/wellcome-sanger/), [Worldwide Cancer Research](https://onco.cc/institutions/worldwide-cancer-research/)

---
JSON: https://onco.cc/api/v1/entities/drug-discovery.json